News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Galena Biopharma  (GALE) To Present GALE-401 (Anagrelide Controlled Release) Phase II Clinical Trial Data At The European Hematology Association 20th Congress 5/22/2015
Complete Data From RegeneRx Biopharmaceuticals, Inc. (RGRX) Phase II Dry Eye Trial Published In Current Issue Of Clinical Ophthalmology 5/22/2015
Otonomy (OTIC) Plunges After Near-Miss Stage IIb Trial for Ear Drug 5/22/2015
Otonomy (OTIC) Reports Phase IIb Topline Data for OTO-104 in Meniere's Disease 5/22/2015
OrthoTrophix Completed Subject Enrollment Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis 5/21/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/21/2015
Lpath (LPTN) Shares Fall 80%, Will Cut Jobs After Second Drug Flunks Phase II Trial 5/21/2015
ICC Cohort Of Delcath Systems (DCTH)'s Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 5/21/2015
CytRx Corporation (CYTR) Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer) 5/21/2015
EMD Serono, Inc. Release: Rebif (interferon beta-1a) Data At CMSC Annual Meeting Highlights Clinical And MRI Predictors For Long Term Outcomes 5/21/2015
Vical Incorporated (VICL) Announces Completion Of Enrollment In Phase II Clinical Trial Of Investigational CMV Vaccine In Kidney Transplant Recipients 5/21/2015
Amarantus BioSciences, Inc. Enters Into CRO Agreement With Chiltern International Ltd. To Commence Phase IIb Clinical Development Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 5/21/2015
Theravance Biopharma Presents Additional Positive Phase 2b Study Data On TD-4208 For Treatment Of COPD At American Thoracic Society 2015 International Conference 5/21/2015
Investors Rejoice as bluebird bio (BLUE) Plots Road to First-Ever U.S. Gene Therapy Approval 5/20/2015
Ardelyx Inc. (ARDX) Presents Positive Results From Its Phase 2b Clinical Trial Evaluating Tenapanor In IBS-C Patients At Digestive Disease Week 2015 5/20/2015
Discovery Laboratories (DSCO) Announces Enrollment Of First Patient In AEROSURF Phase 2a Dose Expansion Trial 5/20/2015
TONIX Pharmaceuticals, Inc. (TNXP) To Present Additional Data From Completed Phase IIb Study Of TNX-102 SL In Fibromyalgia At EULAR 5/20/2015
Cesca Therapeutics Receives IEC/IRB Approval To Initiate Acute Myocardial Infarction Study 5/20/2015
Precision Biologics Completes Patient Accrual To Its Ensituximab Phase II Colorectal Cancer Study 5/20/2015
Kamada Ltd. (KMDA) Reports Updated Data From European Phase II/III Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 5/20/2015
Genocea Biosciences Announces Positive Top-Line Phase 2 Data For Genital Herpes Immunotherapy GEN-003 5/20/2015
Ischemix Announces That Safety Review Committee For CARIN Trial Recommends Phase 2a Study To Continue As Planned 5/20/2015
Amgen (AMGN)'s Migraine Drug Meets Goals in Phase II Study 5/19/2015
Shionogi, Inc. Release: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 5/19/2015
Targovax Announces Presentation Of Data From The Ongoing Phase I/II Clinical Study Of The RAS-Specific Therapeutic Cancer Vaccine TG01 In Resected Pancreatic Cancer At ASCO 2015 In Chicago 5/19/2015
Prima Biomed (PRR.AX) Release: CVAC Shows Overall Survival Benefit In Second Remission Ovarian Cancer In Phase II Study 5/19/2015
Sangamo BioSciences (SGMO) Presents New Data From Proprietary ZFP Therapeutic Programs For Lysosomal Storge Disorders At Annual Meeting Of The American Society Of Gene And Cell Therapy 5/18/2015
Intra-Cellular Therapies, Inc. Announces Further Analyses Of The Phase II Clinical Trial Of ITI-007 In Schizophrenia At The 168th Annual Meeting Of The American Psychiatric Association 5/18/2015
Marinus Pharmaceuticals (MRNS) Presents Clinical Data Of Ganaxolone In Pediatric Epilepsies At Antiepileptic Drug And Device Trials XIII Conference 5/18/2015
Kura Oncology Release: First Patient Dosed In Phase II Study Of Tipifarnib In Advanced Cancers With HRAS Mutations 5/18/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting 5/18/2015
Mesoblast (MSB.AX) Release: Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting 5/18/2015
AbGenomics Corporation Announces Initiation Of Phase-Ib/Iia Clinical Trial Of Neihulizumab (AbGn-168H) For The Treatment Of Steroid Refractory Acute GvHD (aGvHD) 5/18/2015
Immune Pharmaceuticals, Inc. Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready To Enroll Patients 5/18/2015
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results And Provides Corporate Update 5/18/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Pivotal Phase 2b Dupilumab Data In Asthma Presented At The American Thoracic Society 2015 International Conference 5/18/2015
Corbus Receives FDA Clearance To Initiate Phase 2 Clinical Study of Resunab For The Treatment Of Cystic Fibrosis 5/18/2015
Theravance Biopharma Presents Positive Phase 2 Study Data On Velusetrag (TD-5108) For Treatment Of Gastroparesis In "Poster Of Distinction" At Digestive Disease Week (DDW) 2015 5/18/2015
Amgen (AMGN) Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine 5/15/2015
Receptos (RCPT) Announces Oral Plenary Presentation Of TOUCHSTONE Phase II Induction Data At Digestive Disease Week 2015 5/15/2015
TRACON Pharmaceuticals, Inc. (TCON)'s TRC105 Receives FDA Fast Track Designation 5/15/2015
Alder Biopharma Presents Positive Clinical Data For ALD403 At The 17th Congress Of The International Headache Society 5/15/2015
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan For Non-Small Cell Lung Cancer Therapy 5/15/2015
Discovery Laboratories (DSCO) Announces Results Of Phase 2a Clinical Trial Of AEROSURF 5/14/2015
Asterias Biotherapeutics Announces Availability Of Abstract With Phase 2 Clinical Data On Cancer Vaccine AST-VAC1 In Acute Myelogenous Leukemia (AML) 5/14/2015
D-Pharm Ltd. Receives Final Report For Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 5/14/2015
Adynxx Completes Patient Enrollment In Phase 2 Dose-Ranging Study Of AYX1 For Prevention Of Post-Surgical Pain 5/14/2015
Immodulon Therapeutics Release: New Data From IMAGE 1 Show Improved Survival In Metastatic Pancreatic Cancer In Patients Receiving IMM-101 5/14/2015
Astellas Pharma Inc. (ALPMY) Announces New Data In Advanced Prostate And Breast Cancers, Acute Myeloid Leukemia, And Lung And Renal Cancers To Be Presented At 2015 ASCO Annual Meeting 5/14/2015
Sangamo BioSciences (SGMO) Provides Clinical Update On SB-728-T Program and Developments In Other ZFP Therapeutic Programs at American Society of Gene and Cell Therapy Annual Meeting 5/14/2015
Generex Biotechnology Corporation (GNBT) Provides Data Update From AE37 Phase II Breast Cancer Trial One Year Post Completion Of Enrollment 5/14/2015
Genentech (RHHBY)’s Investigational Immunotherapy MPDL3280A Doubled The Likelihood Of Survival Compared With Chemotherapy In People With A Specific Type Of Lung Cancer 5/14/2015
Agenus (AGEN) Announces Oral Presentation At ASCO Highlighting Improved Survival With Prophage Immunotherapy In Brain Cancer Compared To Historical Controls 5/14/2015
Corcept Therapeutics Inc. (CORT)' Mifepristone Combined With Eribulin To Improve Antitumor Activity In Patients With Triple-Negative Breast Cancer 5/14/2015
Teva (TEVA) Presents Further Data From Phase IIb With TEV-48125 In Chronic Migraine At The International Headache Society Congress (IHC): Efficacy And Safety Results At All Doses And Endpoints Present Robust Case For Progression To Phase III 5/14/2015
Celldex (CLDX) To Present Data From The React Study At 2015 ASCO Annual Meeting 5/14/2015
Galectin Therapeutics Reports No Drug-Drug Interaction Between GR-MD-02 And Midazolam 5/14/2015
GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin 5/13/2015
Fibrocell Science, Inc. Receives Rare Pediatric Disease Designation From FDA For FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 5/13/2015
Therabron Therapeutics Secures New Orphan Designation For The Prevention Of Bronchopulmonary Dysplasia 5/13/2015
Discovery Laboratories (DSCO) To Announce Results From AEROSURF Phase 2a Clinical Trial 5/13/2015
AbbVie (ABBV), Genentech (RHHBY) Leukemia Drug Wins Breakthrough Status Tag 5/11/2015
FDA Lifts Clinical Hold on NeuroDerm (NDRM)'s Lead Parkinson's Candidates 5/11/2015
Transition Therapeutics Inc. (TTH.TO) In-Licenses Phase 2 Drug Candidate From Eli Lilly (LLY) 5/11/2015
RXi Pharmaceuticals (RXII) Presented Promising New Data With Self-Delivering RNAi Compounds Targeting Tyrosinase And Collagenase 5/11/2015
TissueGene, Inc. Presents Phase 2 Data For Its Novel Cell Therapy For The Treatment Of Osteoarthritis Of The Knee 5/11/2015
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase II Nash Program 5/11/2015
Amarantus BioSciences, Inc. Reports Preliminary Data From Blood-Based Version Of Msprecise Diagnostic For Multiple Sclerosis 5/11/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Cavendish Global Health Impact Forum 5/11/2015
Can-Fite BioPharma (CFBI)'s Phase II Liver Cancer Trial Approved In Europe 5/11/2015
Zafgen (ZFGN) Presents Positive Safety And Efficacy Data From Phase II Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015 5/8/2015
FDA Grants Fast Track Designation To Sucampo (SCMP)'s Cobiprostone For Oral Mucositis 5/8/2015
Eleven Biotherapeutics (EBIO) Presents Clinical Data On EBI-005 For The Treatment Of Dry Eye Disease And Allergic Conjunctivitis At Association for Research in Vision & Ophthalmology 2015 Annual Meeting 5/8/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Long-Term Administration Of Thymosin B4 In A Diabetic Animal Model Prevents Progression Of Peripheral Neuropathy And Restores Sciatic Nerve Function 5/8/2015
AbbVie (ABBV) And Genentech (RHHBY) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/7/2015
MSI Methylation Sciences, Inc. (MSI) Completes Recruitment Of Phase 2 Trial For Its Novel Treatment STRADA For Major Depressive Disorder (MDD) 5/7/2015
Phosphate Therapeutics Announces Positive Results In The PEACH Pivotal Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 5/7/2015
MediciNova, Inc. Announces Full Enrollment In Phase 2b Trial Of MN-166 (Ibudilast) In Progressive MS 5/7/2015
Otonomy, Inc. (OTIC) Completes Enrollment In Phase II Clinical Trial For Auripro In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes 5/7/2015
Ohr Pharma (OHRP) Presents Data From OHR-102 Phase II IMPACT Study In Wet-AMD At Association for Research in Vision & Ophthalmology Conference 5/7/2015
(MSI) Completes Recruitment Of Phase 2 Trial For Its Novel Treatment STRADA For Major Depressive Disorder (MDD) 5/7/2015
NeuroVive: Published Data Indicates Protective Effect Of Cyclosporine In Patients With Stroke 5/7/2015
Tiny Corbus Looks to Give Vertex (VRTX) Some Competition With Experimental Cystic Fibrosis Drug 5/6/2015
Ardelyx Inc. (ARDX) Reports Results From Phase 2a Clinical Trial Evaluating Tenapanor In Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus And Albuminuria 5/6/2015
AbbVie (ABBV) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/6/2015
GW Pharma (GWPH) Initiates Phase 2 Clinical Study Of Cannabidivarin (CBDV) In Epilepsy 5/6/2015
Parion Sciences Announces Initiation Of Phase 2 Clinical Study Of P-1037 For The Treatment Of Cystic Fibrosis 5/6/2015
Alexion (ALXN) Release: Researchers Present New Data From Phase 2 Clinical Trial Of Eculizumab (Soliris) In Prevention Of Acute Antibody-Mediated Rejection (AMR) In Sensitized Deceased-Donor Kidney Transplant Recipients 5/6/2015
Drug Trial Results For Remedy Pharmaceuticals, Inc.' CIRARA Could Change Stroke Treatment Forever, Saving And Improving Millions Of Lives 5/6/2015
Onxeo : Oral Presentation Of Phase II Trial Results Of Validive At The MASCC/ISOO International Symposium 5/6/2015
Alder Biopharma Announces Presentations At 17th Congress Of The International Headache Society On Data From ALD403 Clinical Trials 5/6/2015
Acacia Pharma Announces Positive Results From Phase 2 Study With APD403 In Chemotherapy Induced Nausea & Vomiting (CINV) 5/6/2015
Merrimack (MACK) Announces Initiation Of A Phase 2 Front-Line Clinical Trial Of MM-141 In Biomarker-Selected Patients With Metastatic Pancreatic Cancer 5/5/2015
Alder Biopharma Release: Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Rheumatoid Arthritis, Meets Primary Endpoint In Follow-On Phase IIb Clinical Trial 5/5/2015
Sorrento Therapeutics, Inc. Shows Off Positive TRIBECA Registrational Study Results 5/4/2015
Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors 5/4/2015
BioLineRx Ltd. Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia 5/4/2015
Aquinox Pharmaceuticals (AQXP) Completes Enrollment In The Phase II KINSHIP Trial Of AQX-1125 In Atopic Dermatitis 5/4/2015
Cortex Pharmaceuticals, Inc. (COR) Announces Publication Of Research Results On The Use Of Ampakines CX1739 And CX717 In The Treatment Of Respiratory Disorders 5/4/2015
Allegro Ophthalmics LLC Begins Phase II Clinical Study Of Luminate® For Non-Proliferative Diabetic Retinopathy 5/4/2015
Generon (Shanghai) Corporation Ltd. Received FDA Clearance To Initiate Phase IIa Study With F-652, A First-In-Class Biologic, To Treat Patients With Acute GvHD 5/4/2015
Kadmon Corporation Initiates Second Phase 2 Clinical Trial Evaluating KD026 In Type 2 Diabetes 5/4/2015
Can-Fite BioPharma (CFBI) Subsidiary, OphthaliX, Signs Term Sheet To Acquire Improved Vision Systems Ltd. 5/4/2015
Auris Medical Holding AG Provides Update On Clinical Development Plan For AM-111 5/4/2015
Shanghai Generon To Start US Trial Of GvHD Biologic Drug 5/4/2015
OncoMed Pharmaceuticals, Inc. (OMED) Publishes Data On Tarextumab's Anti-Cancer Stem Cell Activity In Clinical Cancer Research 5/1/2015
Advanced Inhalation Therapies Granted European Orphan Drug Designation For Nitric Oxide For The Treatment Of Cystic Fibrosis 5/1/2015
TaiGen Biotechnology Starts China Trial Of Novel Chemotherapy Sensitizer 5/1/2015
TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial In Acute Myeloid Leukemia In China 4/30/2015
OncoMed Pharmaceuticals, Inc. (OMED) Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day 4/30/2015
Ocata Therapeutics Announces Positive Results In Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells In Asian Patients 4/30/2015
Eleven Biotherapeutics (EBIO) Publishes Clinical Data On EBI-005 For The Treatment Of Allergic Conjunctivitis 4/29/2015
CytRx Corporation (CYTR) Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy 4/29/2015
Amarantus BioSciences, Inc. Granted European Union Orphan Drug Designation For MANF For The Treatment Of Retinitis Pigmentosa 4/29/2015
Tyrogenex, Inc. Initiates The APEX Study, A Phase II Trial Of Oral Treatment With X-82 For Wet AMD 4/29/2015
Advancing Biogen (BIIB)’s Alzheimer’s Treatment Could Cost $2.5 Billion Before Knowing if the Drug Works 4/28/2015
Celladon (CLDN) Will Lay Off Workers, Loses 80% of Value As Heart Failure Drug Flunks Phase IIb Trial 4/28/2015
Cerulean Pharma Inc. (CERU) Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma 4/28/2015
PRANA Biotechnology (PRAN) Release: PBT2 Recommended For Orphan Designation In Europe 4/28/2015
Bio-Path Holdings, Inc. (BPTH) Granted Orphan Drug Designation For Liposomal Grb-2 In Acute Myeloid Leukemia 4/28/2015
FDA Grants Fast Track Designation To Genzyme (GENZ)’s Investigational Substrate Reduction Therapy For The Treatment Of Fabry Disease 4/28/2015
Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV) 4/27/2015
aTyr Pharma Receives U.S. FDA Orphan Designation For Resolaris 4/27/2015
VentiRx Pharmaceuticals, Inc. Granted Orphan Drug Designation In The European Union For Motolimod In The Treatment Of Ovarian Cancer 4/27/2015
Celsion Corporation (CLSN) Announces Appointment Of Harriet Shelare To Director, Communications 4/27/2015
Achillion (ACHN) Presents Detailed Clinical Results On ACH-3102 And ACH-3422 At The International Liver Congress 4/27/2015
Eiger Biopharma Announces Interim Results Of Lonafarnib In Combination With Ritonavir Or Pegylated Interferon In Patients Infected With Hepatitis Delta Virus (HDV) 4/27/2015
Imperial Innovations Release: Autifony Therapeutics Recruits First Patient Into Phase IIa Trial For Age Related Hearing Loss 4/27/2015
NeuroVive: FIrst Patient Enrolled In Clinical Phase II Study For Kidney Protection During Heart Surgery 4/27/2015
Gilead (GILD) Announces Results From Studies Evaluating Sofosbuvir-Based Regimens In Chronic Hepatitis C Patients With Genotypes 2-5 4/27/2015
Celladon (CLDN) Reports Negative Results For CUPID2 Trial Of MYDICAR In Advanced Heart Failure 4/27/2015
Amgen (AMGN) Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars 4/24/2015
Baseline Characteristics Of 228 Subjects Enrolled In MediciNova, Inc.'s Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS Presented At The American Academy of Neurology 67th Annual Meeting 4/24/2015
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna (DRNA)’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 4/24/2015
Merck & Co. (MRK) Announces Results From Phase 2/3 Study Of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir In Patients With Advanced Chronic Kidney Disease 4/23/2015
Gilead (GILD)’s Harvoni And Sovaldi Demonstrate Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease 4/23/2015
Merck & Co. (MRK) Touts Results From C-SURFER Phase II/III Clinical Trial 4/23/2015
Ultragenyx Pharmaceuticals (RARE) Granted Additional Orphan Drug Designations For Triheptanoin 4/23/2015
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1450 In Staphylococcal Skin Infections 4/23/2015
Conatus Pharma Clinical Results At EASL Meeting Support Emricasan Registration Pathway In NASH 4/23/2015
Intercept Ltd. Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution And Cirrhosis Prevention In High-Risk NASH Patients 4/23/2015
Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome 4/23/2015
Teva (TEVA) And Active Biotech AB (BTPC) Announce First Patient Enrolled In Phase II Study Evaluating Laquinimod For Primary Progressive MS 4/23/2015
Roche (RHHBY) Still Bullish on Alzheimer’s Research After Biogen (BIIB)’s Successful Clinical Trial 4/22/2015
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation 4/22/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome 4/22/2015
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Dosing In Randomized Phase 2 Clinical Trial Of Demcizumab In Pancreatic Cancer Patients 4/22/2015
Genocea Biosciences Completes Enrollment In Phase IIa Human Challenge Study Of GEN-004 For The Prevention Of Infection By Pneumococcus 4/22/2015
Biothera’s Investigational Cancer Immunotherapy Alleviates Immune Suppression By Regulatory T Cells, Enabling CD4 And CD8 T Cell Proliferation, Study Finds 4/22/2015
GlobeImmune, Inc. (GBIM) Announces Opening Of Randomized Phase 2 Chordoma Trial At National Cancer Institute 4/22/2015
Nuvo Research Inc. (NRI.TO) Announces New WF10 Phase 2 Trial 4/22/2015
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study 4/22/2015
Viralytics Ltd (VLA.AX) Update On CALM And STORM Clinical Trials At AACR Annual Meeting 4/22/2015
Pharmaleads Announces The Inclusion Of The First Patient In Phase IIa Study Of Oral PL37 For Pain In Diabetic Neuropathy 4/22/2015
SCRA Technology Ventures Company Shares Phase 2 Results 4/22/2015
Alnylam (ALNY)'s Phase II Study Confirms Effectiveness of RNAi Drugs 4/21/2015
BrainStorm Cell Therapeutics Inc. Says Stem Cell Drug Benefits ALS Patients in Mid-Stage Trial 4/21/2015
Alnylam (ALNY) Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational Rnai Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP) 4/21/2015
Argos Therapeutics, Inc. (ARGS) Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC) 4/21/2015
Genzyme (GENZ) Initiates Phase 2a Clinical Trial To Evaluate Oral Therapy For Fabry Disease 4/21/2015
NeuroVive: Clinical Phase II Study With Neurostat For Traumatic Brain Injury Passes Safety Evaluation 4/21/2015
Biothera’s Imprime PGG Cancer Immunotherapy Drug Candidate Shows Potential To Enhance Efficacy Of Immune Checkpoint Inhibitors 4/21/2015
Biothera’s Imprime PGG Investigational Immunotherapy Drug Modulates The Function Of Macrophages And Dendritic Cells To Drive Expansion Of Anti-Cancer T Cells 4/21/2015
New Data Demonstrate Potential Of Biothera’s Investigational Cancer Immunotherapy To Re-Orient The Tumor Microenvironment To Facilitate Greater Anti-Tumor Activity 4/21/2015
Biothera’s Investigational Cancer Immunotherapy Drug Imprime PGG Elicits Dramatic Expansion Of Cytotoxic T Cells 4/21/2015
FDA Grants Fast Track Designation To Eiger Biopharma's Lonafarnib For Hepatitis Delta Virus (HDV) Infection 4/20/2015
Patients With Advanced Breast, Lung, Esophageal, And Colorectal Cancers Respond To Immunomedics, Inc. (IMMU)' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments 4/20/2015
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015
Anika Therapeutics (ANIK)' Cingal 13-02 Study Meets Primary Endpoint 4/20/2015
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals, Inc.'s NP001 Potential Efficacy And Safety In ALS 4/20/2015
Pluristem Therapeutics (PSTI)'s Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan 4/20/2015
Atara Biotherapeutics (ATRA)' Collaborating Investigators' Abstract On T-Cell Therapy For EBV Lymphoma To Be Presented At A Clinical Trials Plenary Session At The American Association for Cancer Research Annual Meeting 2015 Is Now Available 4/20/2015
Otonomy, Inc. (OTIC) Completes Enrollment Of OTO-104 Multiple-Dose Safety Study In Meniere's Disease Patients 4/20/2015
EBV-CTL Clinical Trial Data Presented By Atara Biotherapeutics' Collaborating Investigators At A Plenary Session At The AACR Annual Meeting 2015 4/20/2015
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015
Nymox Pharmaceutical (NYMX) Announces New Prostate Cancer Clinical Trial Results 4/20/2015
DelMar Pharmaceuticals Presents Updated Clinical Data On Phase I/II Study Of VAL-083 In Refractory Glioblastoma Multiforme (GBM) 4/20/2015
Immunocore Limited Announces Positive Clinical Trial Data For Novel First-in-Class Immunotherapy At AACR Annual Meeting 2015 4/20/2015
Can-Fite BioPharma (CFBI) Applies For Orphan Drug Designation In Europe For CF102 In The Treatment Of Liver Cancer 4/20/2015
Opexa Therapeutics (OPXA) Invited To Present Biomarker Data From NMO Patients At The American Academy of Neurology 2015 Annual Meeting 4/20/2015
Halozyme Therapeutics, Inc. (HALO) Presents New Preclinical Data At AACR Annual Meeting, Announces Clinical Data Presentation At ASCO 4/20/2015
Kamada Ltd. (KMDA) Reports Additional Data From European Phase 2/3 Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 4/20/2015
Pharmacyclics (PCYC) Release: IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, In Patients With Chronic Lymphocytic Leukemia (CLL) 4/20/2015
Bristol-Myers Squibb (BMY) Release: First Randomized Study Evaluating Opdivo (Nivolumab)+Yervoy (Ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma 4/20/2015
Discovery Laboratories (DSCO) Ceasing Production of Lead Drug Surfaxin, Chops 50% Employees 4/17/2015
Athersys (ATHX) Craters as Stem Cell Therapy Fails Phase II Stroke Study 4/17/2015
Targacept (TRGT) Winces As Last Remaining Drug Candidate Flops in Phase II Trial 4/17/2015
RXi Pharmaceuticals (RXII) Receives Orphan Drug Designation For Samcyprone From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb to IV 4/17/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Athersys (ATHX) Announces Results From Phase 2 Study Of Multistem Cell Therapy For Treatment Of Ischemic Stroke 4/17/2015
Anika Therapeutics (ANIK) Reports On Cingal 13-01 Study Clinical Trial Top Line Data And Announces The Completion Of Cingal 13-02 Study’s Patient Enrollment 4/17/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Patients With Non-Diffuse Intrinsic Pontine Glioma 4/17/2015
Ariad (ARIA) Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/17/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Noninfectious Anterior Uveitis Phase II Clinical Trial 4/16/2015
Receptos (RCPT) Reports Positive Results For The Maintenance Period Of The Phase 2 TOUCHSTONE Trial Of Ozanimod In Ulcerative Colitis 4/16/2015
StemCells (STEM) Completes Enrollment Of First Cohort In Phase II Pathway Study For Cervical Spinal Cord Injury 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of NASH With Fibrosis 4/16/2015
Celgene (CELG) Release: Phase II Data For Apremilast In Behçet’s Disease Published In The New England Journal of Medicine 4/16/2015



//-->